Skip to main content
All lobbying filings

S-3 GROUP

Lobbying for SANDOZ INC. · Provider of "off patent" medicines

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $80,000.00 income · posted Jan 16, 2026

Official filing document

 Lobbying activity 1
Health Issues

Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, and PBM reform.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem